 |
|
 |
Oramed Pharmaceuticals (OTC:ORMP.OB) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection. Through its patented flagship product, an oral insulin capsule currently in Phase 2 trials, the Company is seeking to revolutionize the treatment of diabetes. 
|
Press Release
July 7, 2010 June 28, 2010 Results of first exposure of Type 1 diabetes patients to Oramed's oral insulin and of the first-in-human study with its oral GLP-1 analog ... read more » |
| Press Center | Terms & Conditions | Privacy Statement | Design and programming by BIGDESIGN Creative Agency | All rights reserved © 2009 Oramed |